FAQs about Lundbeck

1. What is Lundbeck’s business area?
H. Lundbeck A/S is an international pharmaceutical company engaged in research and development, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders.

2. What is Lundbeck’s vision?
Lundbeck’s vision is to become a world leader in the development of pharmaceuticals for psychiatric and neurological diseases.

3. What is Lundbeck’s mission?
Lundbeck’s mission is to improve the quality of life for people suffering from psychiatric and neurological diseases.

4. Where does Lundbeck operate plants, sales offices, etc.?
Lundbeck is an international pharmaceutical company with representation in 54 countries. At Lundbeck’s website you can find details about the location of Lundbeck’s factories and sales companies.

5. How many people work at Lundbeck?
More than 5,300 employees.

6. How much revenue does Lundbeck generate?
Lundbeck’s 2007 revenue amounted to DKK 10,985 million.

7. When was Lundbeck founded?
Lundbeck was founded by Hans Lundbeck in 1915. More information on Lundbeck’s history is available at the company’s website: http://www.lundbeck.com/aboutus/history/Milestones/

8. What does the Lundbeck Institute do?
The Lundbeck Institute was founded in 1997, and its objective is, through education and information, to improve treatment for patients suffering from psychiatric and neurological diseases. Further information on the Lundbeck Institute is available at: http://www.cnsforum.com
 
9. Which products does Lundbeck market?
Lundbeck focuses entirely on central nervous system disorders, marketing drugs for the treatment of depression, anxiety disorders, schizophrenia and Alzheimer’s disease.

Since 2002, Lundbeck has marketed four new pharmaceuticals – Cipralex®/Lexapro® for the treatment of depression and anxiety, Ebixa® for the treatment of Alzheimer’s disease, Azilect® for the treatment of Parkinson’s disease and Serdolect® for the
treatment of schizophrenia.

In terms of revenue, Cipralex®/Lexapro® is Lundbeck’s largest pharmaceutical, followed by Ebixa®. Both pharmaceuticals were launched in the first markets in 2002. Since being
launched in 2005, Azilect® has exceeded management’s sales expectations, while Serdolect ®, launched in 2006, has fallen short of expectations. Lundbeck expects to launch its new pharmaceutical Circadin® for the treatment of primary insomnia in the first markets in 2008.

Lundbeck’s mature pharmaceuticals represent a stable foundation for consolidated revenue, with the exception of citalopram, the revenue of which continued to decline in 2007 due to generic competition. Lundbeck expects that citalopram revenue will continue to decline in 2008, albeit at a slower pace than previously.

Cipralex®/Lexapro® (escitalopram) – depression and anxiety
Cipralex®/Lexapro® is the most frequently prescribed branded pharmaceutical for the treatment of depression, both in the USA and in Europe and the second most prescribed in International Markets.

10. How much does Lundbeck invest in R&D?
Each year, Lundbeck invests around 20% of its revenue in R&D and the development of new, innovative drugs, and this is substantially above the industry average of about 17%. In 2007, Lundbeck’s R&D costs amounted to DKK 2,187 million.

11. How do I get a copy of the annual report?
You are able to read the Annual Report as a Pdf file at Lundbeck’s website. You are also able to order a printed copy of the report from the website. http://www.lundbeck.com/investor/reports/annual_reports/default.asp